Default company panoramic image


If you want to cure a disease, start with the immune system of a person that's already done it.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Employees 3
  • Website

Company Summary

Immunome is a start-up biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system. Our novel antibodies have superior properties compared to those made by artificial systems such as mice or bacteria. We are using this game-changing technology to develop novel therapies for diseases which currently have no or inadequate treatment options.


  • Default avatar
    Timothy J. Pelura
    Chairman, President and CEO

    Dr. Pelura joined Immunome in September of 2009 as President and CEO. He is a serial life science entrepreneur with over 35 years of experience in the pharmaceutical, biotech and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas. He has several successful financings and exits to his credit.
    Dr. Pelura holds a Ph.D. in chemistry from Rutgers University.

  • Default avatar
    Scott K. Dessain
    Chief Scientific Officer

    Dr. Dessain is an Associate Professor at the Lankenau Institute for Medical Research, Wynnewood PA. He received M.D. and Ph.D. degrees from Yale University in 1994. He pursued post-graduate medical training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Medical Oncology at Dana Farber/Partners Cancer Care Boston, MA. His post-doctoral training was with Dr. Robert Weinberg at the Whitehead Institute in Cambridge,

  • Default avatar
    George D. Hobbs
    SVP Corporate Development and General Counsel

    Mr. Hobbs has more than 20 years of experience in the life science industry. Before joining Immunome in 2009, George had a leadership role in the formation and management of a start-up company that advanced a novel cellular therapy from discovery to clinical testing. He was also a member of the senior management team for 13 years at Centocor, Inc. during the successful development of several products; and a $4.9 billion merger with J&J.


  • Default avatar
    Kathleen M. Shay, Duane Morris LLP
    Default avatar
    Morris Gocial, Gold Gocial Gerstein LLC

Previous Investors

  • Default avatar
    Default avatar
    I. Wistar Morris
    Default avatar
    Michael Widlitz